Prostacyclin
Top View
- Clinical Policy: Iloprost (Ventavis) Reference Number: CP.PHAR.193 Effective Date: 03/16 Coding Implications Last Review Date: 03/17 Revision Log
- Effects of Beraprost Sodium, an Oral Prostacyclin Analogue, in Patients
- Increased Role of E Prostanoid Receptor-3 in Prostacyclin
- Ventavis, INN-Iloprost
- Theranostics Multi-Omics Study of Silicosis Reveals the Potential
- Cycle Network Model of Prostaglandin H Synthase-1
- The Mechanistic Basis for Prostacyclin Action in Pulmonary Hypertension
- Gastrointestinal Safety of AZD3582, a Cyclooxygenase Inhibiting
- CVMP Acetylsalicylic Acid & Salts Summary Report
- Best Practice in CRRT Anticoagulation
- Multiple Roles of Prostaglandin E2 Receptors in Female Reproduction
- Why Do Cyclo-Oxygenase-2 Inhibitors Cause Cardiovascular Events? Richard J
- Neuronal Prostaglandin E2 Receptor Subtype EP3 Mediates Antinociception During Inflammation
- Anticoagulation During Cardiopulmonary Bypass
- Concentrations of Prostaglandin Endoperoxide Synthase and Prostaglandin I2 Synthase in the Endothelium and Smooth Muscle of Bovine Aorta
- Ventavis® (Iloprost) Inhalation Solution RX Only
- Beraprost Sodium, a Stable Prostacyclin Analogue, Improves Insulin Resistance in High-Fat Diet-Induced Obese Mice
- Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)